nodes	percent_of_prediction	percent_of_DWPC	metapath
Vidarabine—ADA—myometrium—ovarian cancer	0.0175	0.0574	CbGeAlD
Vidarabine—Tenofovir—NME2—ovarian cancer	0.0144	0.512	CrCbGaD
Vidarabine—ADK—myometrium—ovarian cancer	0.0143	0.0469	CbGeAlD
Vidarabine—ADK—Nucleotide metabolism—NME2—ovarian cancer	0.014	0.0879	CbGpPWpGaD
Vidarabine—DPP4—embryo—ovarian cancer	0.0133	0.0437	CbGeAlD
Vidarabine—ADA—decidua—ovarian cancer	0.0129	0.0426	CbGeAlD
Vidarabine—ADK—uterine cervix—ovarian cancer	0.0111	0.0365	CbGeAlD
Vidarabine—DPP4—epithelium—ovarian cancer	0.0109	0.0357	CbGeAlD
Vidarabine—DPP4—uterine cervix—ovarian cancer	0.0108	0.0354	CbGeAlD
Vidarabine—ADK—decidua—ovarian cancer	0.0106	0.0348	CbGeAlD
Vidarabine—ADORA2A—gonad—ovarian cancer	0.0104	0.0341	CbGeAlD
Vidarabine—DPP4—decidua—ovarian cancer	0.0103	0.0337	CbGeAlD
Vidarabine—ADA—female reproductive system—ovarian cancer	0.0102	0.0335	CbGeAlD
Vidarabine—ADK—endometrium—ovarian cancer	0.01	0.033	CbGeAlD
Vidarabine—DPP4—endometrium—ovarian cancer	0.00973	0.032	CbGeAlD
Vidarabine—ADA—bone marrow—ovarian cancer	0.00961	0.0316	CbGeAlD
Vidarabine—ADA—Nucleotide metabolism—NME2—ovarian cancer	0.00951	0.0597	CbGpPWpGaD
Vidarabine—ADK—gonad—ovarian cancer	0.00931	0.0306	CbGeAlD
Vidarabine—ADORA2A—female reproductive system—ovarian cancer	0.00926	0.0304	CbGeAlD
Vidarabine—ADA—vagina—ovarian cancer	0.0092	0.0303	CbGeAlD
Vidarabine—DPP4—uterus—ovarian cancer	0.00897	0.0295	CbGeAlD
Vidarabine—ADK—female reproductive system—ovarian cancer	0.00831	0.0273	CbGeAlD
Vidarabine—ADA—testis—ovarian cancer	0.00821	0.027	CbGeAlD
Vidarabine—DPP4—female reproductive system—ovarian cancer	0.00806	0.0265	CbGeAlD
Vidarabine—ADK—bone marrow—ovarian cancer	0.00785	0.0258	CbGeAlD
Vidarabine—DPP4—bone marrow—ovarian cancer	0.00761	0.025	CbGeAlD
Vidarabine—ADK—female gonad—ovarian cancer	0.00757	0.0249	CbGeAlD
Vidarabine—ADK—vagina—ovarian cancer	0.00752	0.0247	CbGeAlD
Vidarabine—ADORA2A—testis—ovarian cancer	0.00747	0.0246	CbGeAlD
Vidarabine—DPP4—female gonad—ovarian cancer	0.00733	0.0241	CbGeAlD
Vidarabine—DPP4—vagina—ovarian cancer	0.00729	0.024	CbGeAlD
Vidarabine—Cladribine—NR5A1—ovarian cancer	0.00693	0.246	CrCbGaD
Vidarabine—DPP4—Peptide hormone metabolism—INHA—ovarian cancer	0.00686	0.0431	CbGpPWpGaD
Vidarabine—ADK—testis—ovarian cancer	0.00671	0.0221	CbGeAlD
Vidarabine—ADA—Validated transcriptional targets of deltaNp63 isoforms—TP63—ovarian cancer	0.00655	0.0411	CbGpPWpGaD
Vidarabine—DPP4—testis—ovarian cancer	0.00651	0.0214	CbGeAlD
Vidarabine—ADA—lymph node—ovarian cancer	0.00595	0.0196	CbGeAlD
Vidarabine—ADA—Validated transcriptional targets of TAp63 isoforms—TP63—ovarian cancer	0.00586	0.0368	CbGpPWpGaD
Vidarabine—ADORA2A—Monoamine Transport—RBL2—ovarian cancer	0.00576	0.0362	CbGpPWpGaD
Vidarabine—ADA—Validated transcriptional targets of deltaNp63 isoforms—YAP1—ovarian cancer	0.00539	0.0338	CbGpPWpGaD
Vidarabine—ADORA2A—Monoamine Transport—PVRL2—ovarian cancer	0.00524	0.0329	CbGpPWpGaD
Vidarabine—ADK—lymph node—ovarian cancer	0.00486	0.016	CbGeAlD
Vidarabine—DPP4—lymph node—ovarian cancer	0.00472	0.0155	CbGeAlD
Vidarabine—ADA—Validated transcriptional targets of deltaNp63 isoforms—FASN—ovarian cancer	0.00439	0.0276	CbGpPWpGaD
Vidarabine—ADA—p73 transcription factor network—TP63—ovarian cancer	0.00432	0.0271	CbGpPWpGaD
Vidarabine—DPP4—Synthesis, secretion, and inactivation of Glucagon-like Peptide-1 (GLP-1)—CTNNB1—ovarian cancer	0.00399	0.0251	CbGpPWpGaD
Vidarabine—ADA—Validated transcriptional targets of TAp63 isoforms—GADD45A—ovarian cancer	0.00393	0.0247	CbGpPWpGaD
Vidarabine—Glucosamine—MMP9—ovarian cancer	0.00386	0.137	CrCbGaD
Vidarabine—ADA—p73 transcription factor network—YAP1—ovarian cancer	0.00356	0.0223	CbGpPWpGaD
Vidarabine—DPP4—Incretin synthesis, secretion, and inactivation—CTNNB1—ovarian cancer	0.00355	0.0223	CbGpPWpGaD
Vidarabine—ADA—Validated transcriptional targets of deltaNp63 isoforms—BRCA2—ovarian cancer	0.0034	0.0214	CbGpPWpGaD
Vidarabine—ADK—Nucleotide metabolism—TYMS—ovarian cancer	0.00318	0.0199	CbGpPWpGaD
Vidarabine—ADORA2A—HIF-2-alpha transcription factor network—SLC2A1—ovarian cancer	0.00311	0.0195	CbGpPWpGaD
Vidarabine—ADA—p73 transcription factor network—FASN—ovarian cancer	0.0029	0.0182	CbGpPWpGaD
Vidarabine—ADA—Circadian rythm related genes—TOP1—ovarian cancer	0.00288	0.018	CbGpPWpGaD
Vidarabine—ADA—Circadian rythm related genes—PPP1CC—ovarian cancer	0.00251	0.0158	CbGpPWpGaD
Vidarabine—Adenosine triphosphate—AKT1—ovarian cancer	0.00248	0.0883	CrCbGaD
Vidarabine—ADA—p73 transcription factor network—BRCA2—ovarian cancer	0.00225	0.0141	CbGpPWpGaD
Vidarabine—ADA—Circadian rythm related genes—HNF1B—ovarian cancer	0.00218	0.0137	CbGpPWpGaD
Vidarabine—ADA—Nucleotide metabolism—TYMS—ovarian cancer	0.00216	0.0135	CbGpPWpGaD
Vidarabine—DPP4—Metabolism of proteins—MUC16—ovarian cancer	0.00201	0.0126	CbGpPWpGaD
Vidarabine—ADORA2A—Circadian rythm related genes—TOP1—ovarian cancer	0.00165	0.0104	CbGpPWpGaD
Vidarabine—Chest pain—Melphalan—ovarian cancer	0.00161	0.00317	CcSEcCtD
Vidarabine—Ventricular extrasystoles—Epirubicin—ovarian cancer	0.00161	0.00317	CcSEcCtD
Vidarabine—Cardiac failure—Docetaxel—ovarian cancer	0.00161	0.00316	CcSEcCtD
Vidarabine—Back pain—Vinorelbine—ovarian cancer	0.0016	0.00315	CcSEcCtD
Vidarabine—Anaphylactic shock—Topotecan—ovarian cancer	0.00158	0.0031	CcSEcCtD
Vidarabine—Anaphylactic shock—Melphalan—ovarian cancer	0.00155	0.00304	CcSEcCtD
Vidarabine—Hyperhidrosis—Topotecan—ovarian cancer	0.00153	0.003	CcSEcCtD
Vidarabine—Pain—Chlorambucil—ovarian cancer	0.00152	0.00298	CcSEcCtD
Vidarabine—Angioedema—Vinorelbine—ovarian cancer	0.00151	0.00297	CcSEcCtD
Vidarabine—Tachycardia—Melphalan—ovarian cancer	0.00151	0.00297	CcSEcCtD
Vidarabine—Atrioventricular block—Epirubicin—ovarian cancer	0.0015	0.00295	CcSEcCtD
Vidarabine—Ventricular extrasystoles—Doxorubicin—ovarian cancer	0.00149	0.00293	CcSEcCtD
Vidarabine—Pollakiuria—Paclitaxel—ovarian cancer	0.00148	0.0029	CcSEcCtD
Vidarabine—Palpitations—Vinorelbine—ovarian cancer	0.00146	0.00288	CcSEcCtD
Vidarabine—Ventricular tachycardia—Epirubicin—ovarian cancer	0.00146	0.00286	CcSEcCtD
Vidarabine—Injection site reaction—Epirubicin—ovarian cancer	0.00145	0.00285	CcSEcCtD
Vidarabine—Hypotension—Melphalan—ovarian cancer	0.00144	0.00284	CcSEcCtD
Vidarabine—Cough—Vinorelbine—ovarian cancer	0.00144	0.00284	CcSEcCtD
Vidarabine—ADORA2A—Circadian rythm related genes—PPP1CC—ovarian cancer	0.00144	0.00906	CbGpPWpGaD
Vidarabine—Musculoskeletal discomfort—Topotecan—ovarian cancer	0.00144	0.00283	CcSEcCtD
Vidarabine—Hypertension—Vinorelbine—ovarian cancer	0.00143	0.00281	CcSEcCtD
Vidarabine—Paraesthesia—Topotecan—ovarian cancer	0.00142	0.00279	CcSEcCtD
Vidarabine—Urticaria—Chlorambucil—ovarian cancer	0.00141	0.00277	CcSEcCtD
Vidarabine—Chest pain—Vinorelbine—ovarian cancer	0.00141	0.00277	CcSEcCtD
Vidarabine—Musculoskeletal discomfort—Melphalan—ovarian cancer	0.00141	0.00277	CcSEcCtD
Vidarabine—Dyspnoea—Topotecan—ovarian cancer	0.00141	0.00277	CcSEcCtD
Vidarabine—Acute coronary syndrome—Paclitaxel—ovarian cancer	0.0014	0.00276	CcSEcCtD
Vidarabine—Myocardial infarction—Paclitaxel—ovarian cancer	0.0014	0.00275	CcSEcCtD
Vidarabine—Discomfort—Vinorelbine—ovarian cancer	0.00139	0.00274	CcSEcCtD
Vidarabine—Atrioventricular block—Doxorubicin—ovarian cancer	0.00139	0.00273	CcSEcCtD
Vidarabine—Paraesthesia—Melphalan—ovarian cancer	0.00139	0.00273	CcSEcCtD
Vidarabine—Dyspnoea—Melphalan—ovarian cancer	0.00138	0.00271	CcSEcCtD
Vidarabine—Anaphylactic shock—Vinorelbine—ovarian cancer	0.00135	0.00266	CcSEcCtD
Vidarabine—Pain—Topotecan—ovarian cancer	0.00135	0.00266	CcSEcCtD
Vidarabine—Ventricular tachycardia—Doxorubicin—ovarian cancer	0.00135	0.00265	CcSEcCtD
Vidarabine—Injection site reaction—Doxorubicin—ovarian cancer	0.00134	0.00263	CcSEcCtD
Vidarabine—Bronchospasm—Docetaxel—ovarian cancer	0.00133	0.00262	CcSEcCtD
Vidarabine—Pain—Melphalan—ovarian cancer	0.00132	0.0026	CcSEcCtD
Vidarabine—Tachycardia—Vinorelbine—ovarian cancer	0.00132	0.00259	CcSEcCtD
Vidarabine—Hypersensitivity—Chlorambucil—ovarian cancer	0.00131	0.00257	CcSEcCtD
Vidarabine—Bradycardia—Paclitaxel—ovarian cancer	0.0013	0.00256	CcSEcCtD
Vidarabine—DPP4—Metabolism of proteins—INHA—ovarian cancer	0.0013	0.00813	CbGpPWpGaD
Vidarabine—Asthenia—Chlorambucil—ovarian cancer	0.00127	0.0025	CcSEcCtD
Vidarabine—Hypoaesthesia—Paclitaxel—ovarian cancer	0.00127	0.0025	CcSEcCtD
Vidarabine—ADK—Metabolism—NME2—ovarian cancer	0.00127	0.00798	CbGpPWpGaD
Vidarabine—Hypotension—Vinorelbine—ovarian cancer	0.00126	0.00248	CcSEcCtD
Vidarabine—Urticaria—Topotecan—ovarian cancer	0.00125	0.00247	CcSEcCtD
Vidarabine—ADORA2A—Circadian rythm related genes—HNF1B—ovarian cancer	0.00125	0.00786	CbGpPWpGaD
Vidarabine—Musculoskeletal discomfort—Vinorelbine—ovarian cancer	0.00123	0.00242	CcSEcCtD
Vidarabine—Urticaria—Melphalan—ovarian cancer	0.00123	0.00242	CcSEcCtD
Vidarabine—Paraesthesia—Vinorelbine—ovarian cancer	0.00121	0.00238	CcSEcCtD
Vidarabine—DPP4—Peptide hormone metabolism—CTNNB1—ovarian cancer	0.0012	0.00756	CbGpPWpGaD
Vidarabine—Dyspnoea—Vinorelbine—ovarian cancer	0.0012	0.00237	CcSEcCtD
Vidarabine—Tinnitus—Paclitaxel—ovarian cancer	0.00119	0.00234	CcSEcCtD
Vidarabine—Acute coronary syndrome—Docetaxel—ovarian cancer	0.00119	0.00234	CcSEcCtD
Vidarabine—Cardiac disorder—Paclitaxel—ovarian cancer	0.00119	0.00233	CcSEcCtD
Vidarabine—Flushing—Paclitaxel—ovarian cancer	0.00119	0.00233	CcSEcCtD
Vidarabine—Myocardial infarction—Docetaxel—ovarian cancer	0.00118	0.00233	CcSEcCtD
Vidarabine—Hypersensitivity—Topotecan—ovarian cancer	0.00116	0.00229	CcSEcCtD
Vidarabine—Pain—Vinorelbine—ovarian cancer	0.00115	0.00227	CcSEcCtD
Vidarabine—Mediastinal disorder—Paclitaxel—ovarian cancer	0.00115	0.00227	CcSEcCtD
Vidarabine—Arrhythmia—Paclitaxel—ovarian cancer	0.00114	0.00225	CcSEcCtD
Vidarabine—Hypersensitivity—Melphalan—ovarian cancer	0.00114	0.00224	CcSEcCtD
Vidarabine—Asthenia—Topotecan—ovarian cancer	0.00113	0.00223	CcSEcCtD
Vidarabine—Vomiting—Chlorambucil—ovarian cancer	0.00113	0.00222	CcSEcCtD
Vidarabine—Asthenia—Melphalan—ovarian cancer	0.00111	0.00218	CcSEcCtD
Vidarabine—Tension—Paclitaxel—ovarian cancer	0.00109	0.00215	CcSEcCtD
Vidarabine—Dysgeusia—Paclitaxel—ovarian cancer	0.00109	0.00214	CcSEcCtD
Vidarabine—Cardiac failure—Epirubicin—ovarian cancer	0.00108	0.00213	CcSEcCtD
Vidarabine—Nervousness—Paclitaxel—ovarian cancer	0.00108	0.00213	CcSEcCtD
Vidarabine—Hypoaesthesia—Docetaxel—ovarian cancer	0.00108	0.00212	CcSEcCtD
Vidarabine—Cerebrovascular accident—Epirubicin—ovarian cancer	0.00108	0.00212	CcSEcCtD
Vidarabine—Back pain—Paclitaxel—ovarian cancer	0.00108	0.00212	CcSEcCtD
Vidarabine—ADA—C-MYB transcription factor network—CDKN1B—ovarian cancer	0.00107	0.00674	CbGpPWpGaD
Vidarabine—Urticaria—Vinorelbine—ovarian cancer	0.00107	0.00211	CcSEcCtD
Vidarabine—ADORA2A—HIF-2-alpha transcription factor network—VEGFA—ovarian cancer	0.00106	0.00664	CbGpPWpGaD
Vidarabine—Nausea—Chlorambucil—ovarian cancer	0.00105	0.00207	CcSEcCtD
Vidarabine—Vision blurred—Paclitaxel—ovarian cancer	0.00105	0.00206	CcSEcCtD
Vidarabine—Dizziness—Topotecan—ovarian cancer	0.00104	0.00205	CcSEcCtD
Vidarabine—Tremor—Paclitaxel—ovarian cancer	0.00104	0.00205	CcSEcCtD
Vidarabine—Affect lability—Epirubicin—ovarian cancer	0.00104	0.00205	CcSEcCtD
Vidarabine—ADA—C-MYB transcription factor network—CCND1—ovarian cancer	0.00102	0.00643	CbGpPWpGaD
Vidarabine—Agitation—Paclitaxel—ovarian cancer	0.00102	0.00201	CcSEcCtD
Vidarabine—Angioedema—Paclitaxel—ovarian cancer	0.00102	0.002	CcSEcCtD
Vidarabine—ADA—Circadian rythm related genes—TYMS—ovarian cancer	0.00101	0.00635	CbGpPWpGaD
Vidarabine—Flushing—Docetaxel—ovarian cancer	0.00101	0.00198	CcSEcCtD
Vidarabine—Cardiac disorder—Docetaxel—ovarian cancer	0.00101	0.00198	CcSEcCtD
Vidarabine—Cardiac arrest—Epirubicin—ovarian cancer	0.001	0.00198	CcSEcCtD
Vidarabine—Vomiting—Topotecan—ovarian cancer	0.001	0.00197	CcSEcCtD
Vidarabine—Cardiac failure—Doxorubicin—ovarian cancer	0.001	0.00197	CcSEcCtD
Vidarabine—Mood swings—Epirubicin—ovarian cancer	0.001	0.00197	CcSEcCtD
Vidarabine—Syncope—Paclitaxel—ovarian cancer	0.000998	0.00196	CcSEcCtD
Vidarabine—Cerebrovascular accident—Doxorubicin—ovarian cancer	0.000998	0.00196	CcSEcCtD
Vidarabine—Rash—Topotecan—ovarian cancer	0.000995	0.00196	CcSEcCtD
Vidarabine—Hypersensitivity—Vinorelbine—ovarian cancer	0.000995	0.00196	CcSEcCtD
Vidarabine—Dermatitis—Topotecan—ovarian cancer	0.000994	0.00196	CcSEcCtD
Vidarabine—Headache—Topotecan—ovarian cancer	0.000989	0.00195	CcSEcCtD
Vidarabine—Palpitations—Paclitaxel—ovarian cancer	0.000984	0.00193	CcSEcCtD
Vidarabine—Vomiting—Melphalan—ovarian cancer	0.000983	0.00193	CcSEcCtD
Vidarabine—Loss of consciousness—Paclitaxel—ovarian cancer	0.000978	0.00192	CcSEcCtD
Vidarabine—Mediastinal disorder—Docetaxel—ovarian cancer	0.000977	0.00192	CcSEcCtD
Vidarabine—Rash—Melphalan—ovarian cancer	0.000975	0.00192	CcSEcCtD
Vidarabine—Dermatitis—Melphalan—ovarian cancer	0.000974	0.00192	CcSEcCtD
Vidarabine—Cough—Paclitaxel—ovarian cancer	0.000971	0.00191	CcSEcCtD
Vidarabine—Asthenia—Vinorelbine—ovarian cancer	0.000969	0.00191	CcSEcCtD
Vidarabine—Arrhythmia—Docetaxel—ovarian cancer	0.000968	0.0019	CcSEcCtD
Vidarabine—Convulsion—Paclitaxel—ovarian cancer	0.000964	0.0019	CcSEcCtD
Vidarabine—Affect lability—Doxorubicin—ovarian cancer	0.000962	0.00189	CcSEcCtD
Vidarabine—Hypertension—Paclitaxel—ovarian cancer	0.000961	0.00189	CcSEcCtD
Vidarabine—Chest pain—Paclitaxel—ovarian cancer	0.000948	0.00186	CcSEcCtD
Vidarabine—Anxiety—Paclitaxel—ovarian cancer	0.000944	0.00186	CcSEcCtD
Vidarabine—Nausea—Topotecan—ovarian cancer	0.000938	0.00184	CcSEcCtD
Vidarabine—Discomfort—Paclitaxel—ovarian cancer	0.000936	0.00184	CcSEcCtD
Vidarabine—Cardiac arrest—Doxorubicin—ovarian cancer	0.00093	0.00183	CcSEcCtD
Vidarabine—Dry mouth—Paclitaxel—ovarian cancer	0.000927	0.00182	CcSEcCtD
Vidarabine—Mood swings—Doxorubicin—ovarian cancer	0.000926	0.00182	CcSEcCtD
Vidarabine—Dysgeusia—Docetaxel—ovarian cancer	0.000924	0.00182	CcSEcCtD
Vidarabine—Nausea—Melphalan—ovarian cancer	0.000918	0.00181	CcSEcCtD
Vidarabine—DPP4—Metabolism of proteins—TUBB3—ovarian cancer	0.000913	0.00573	CbGpPWpGaD
Vidarabine—Back pain—Docetaxel—ovarian cancer	0.000913	0.00179	CcSEcCtD
Vidarabine—Anaphylactic shock—Paclitaxel—ovarian cancer	0.000908	0.00179	CcSEcCtD
Vidarabine—Shock—Paclitaxel—ovarian cancer	0.000894	0.00176	CcSEcCtD
Vidarabine—Dizziness—Vinorelbine—ovarian cancer	0.000893	0.00176	CcSEcCtD
Vidarabine—Tachycardia—Paclitaxel—ovarian cancer	0.000887	0.00174	CcSEcCtD
Vidarabine—ADORA2A—NGF signalling via TRKA from the plasma membrane—EREG—ovarian cancer	0.000885	0.00555	CbGpPWpGaD
Vidarabine—ADA—C-MYB transcription factor network—NRAS—ovarian cancer	0.000882	0.00554	CbGpPWpGaD
Vidarabine—Hyperhidrosis—Paclitaxel—ovarian cancer	0.000878	0.00173	CcSEcCtD
Vidarabine—ADA—Metabolism—NME2—ovarian cancer	0.000864	0.00543	CbGpPWpGaD
Vidarabine—ADA—p73 transcription factor network—MYC—ovarian cancer	0.000863	0.00542	CbGpPWpGaD
Vidarabine—Vomiting—Vinorelbine—ovarian cancer	0.000859	0.00169	CcSEcCtD
Vidarabine—Rash—Vinorelbine—ovarian cancer	0.000852	0.00167	CcSEcCtD
Vidarabine—Dermatitis—Vinorelbine—ovarian cancer	0.000851	0.00167	CcSEcCtD
Vidarabine—Hypotension—Paclitaxel—ovarian cancer	0.000849	0.00167	CcSEcCtD
Vidarabine—Headache—Vinorelbine—ovarian cancer	0.000846	0.00166	CcSEcCtD
Vidarabine—Syncope—Docetaxel—ovarian cancer	0.000846	0.00166	CcSEcCtD
Vidarabine—Pollakiuria—Epirubicin—ovarian cancer	0.000844	0.00166	CcSEcCtD
Vidarabine—Palpitations—Docetaxel—ovarian cancer	0.000834	0.00164	CcSEcCtD
Vidarabine—Loss of consciousness—Docetaxel—ovarian cancer	0.000829	0.00163	CcSEcCtD
Vidarabine—Musculoskeletal discomfort—Paclitaxel—ovarian cancer	0.000828	0.00163	CcSEcCtD
Vidarabine—Cough—Docetaxel—ovarian cancer	0.000823	0.00162	CcSEcCtD
Vidarabine—ADA—C-MYB transcription factor network—MYC—ovarian cancer	0.000822	0.00516	CbGpPWpGaD
Vidarabine—ADK—Metabolism—CYTB—ovarian cancer	0.000819	0.00514	CbGpPWpGaD
Vidarabine—Convulsion—Docetaxel—ovarian cancer	0.000817	0.00161	CcSEcCtD
Vidarabine—Paraesthesia—Paclitaxel—ovarian cancer	0.000816	0.0016	CcSEcCtD
Vidarabine—Hypertension—Docetaxel—ovarian cancer	0.000814	0.0016	CcSEcCtD
Vidarabine—Drowsiness—Epirubicin—ovarian cancer	0.000814	0.0016	CcSEcCtD
Vidarabine—Dyspnoea—Paclitaxel—ovarian cancer	0.00081	0.00159	CcSEcCtD
Vidarabine—Somnolence—Paclitaxel—ovarian cancer	0.000808	0.00159	CcSEcCtD
Vidarabine—Chest pain—Docetaxel—ovarian cancer	0.000803	0.00158	CcSEcCtD
Vidarabine—Nausea—Vinorelbine—ovarian cancer	0.000802	0.00158	CcSEcCtD
Vidarabine—Dry mouth—Docetaxel—ovarian cancer	0.000785	0.00154	CcSEcCtD
Vidarabine—Sweating—Epirubicin—ovarian cancer	0.000781	0.00154	CcSEcCtD
Vidarabine—Pollakiuria—Doxorubicin—ovarian cancer	0.000781	0.00154	CcSEcCtD
Vidarabine—Pain—Paclitaxel—ovarian cancer	0.000777	0.00153	CcSEcCtD
Vidarabine—DPP4—Metabolism of proteins—ATF3—ovarian cancer	0.000771	0.00484	CbGpPWpGaD
Vidarabine—Anaphylactic shock—Docetaxel—ovarian cancer	0.00077	0.00151	CcSEcCtD
Vidarabine—ADA—C-MYB transcription factor network—KRAS—ovarian cancer	0.000759	0.00476	CbGpPWpGaD
Vidarabine—Shock—Docetaxel—ovarian cancer	0.000757	0.00149	CcSEcCtD
Vidarabine—Drowsiness—Doxorubicin—ovarian cancer	0.000753	0.00148	CcSEcCtD
Vidarabine—Tachycardia—Docetaxel—ovarian cancer	0.000751	0.00148	CcSEcCtD
Vidarabine—Bradycardia—Epirubicin—ovarian cancer	0.000744	0.00146	CcSEcCtD
Vidarabine—Hypoaesthesia—Epirubicin—ovarian cancer	0.000727	0.00143	CcSEcCtD
Vidarabine—Sweating—Doxorubicin—ovarian cancer	0.000722	0.00142	CcSEcCtD
Vidarabine—Urticaria—Paclitaxel—ovarian cancer	0.000722	0.00142	CcSEcCtD
Vidarabine—Hypotension—Docetaxel—ovarian cancer	0.000719	0.00141	CcSEcCtD
Vidarabine—ADK—Metabolism—PPP1CC—ovarian cancer	0.000716	0.0045	CbGpPWpGaD
Vidarabine—ADK—Metabolism—BRIP1—ovarian cancer	0.000716	0.0045	CbGpPWpGaD
Vidarabine—Musculoskeletal discomfort—Docetaxel—ovarian cancer	0.000701	0.00138	CcSEcCtD
Vidarabine—Paraesthesia—Docetaxel—ovarian cancer	0.000691	0.00136	CcSEcCtD
Vidarabine—Bradycardia—Doxorubicin—ovarian cancer	0.000689	0.00135	CcSEcCtD
Vidarabine—Dyspnoea—Docetaxel—ovarian cancer	0.000686	0.00135	CcSEcCtD
Vidarabine—Somnolence—Docetaxel—ovarian cancer	0.000684	0.00135	CcSEcCtD
Vidarabine—Tinnitus—Epirubicin—ovarian cancer	0.000682	0.00134	CcSEcCtD
Vidarabine—ADORA2A—Signaling by NGF—EREG—ovarian cancer	0.00068	0.00427	CbGpPWpGaD
Vidarabine—Flushing—Epirubicin—ovarian cancer	0.000678	0.00133	CcSEcCtD
Vidarabine—Cardiac disorder—Epirubicin—ovarian cancer	0.000678	0.00133	CcSEcCtD
Vidarabine—Hypoaesthesia—Doxorubicin—ovarian cancer	0.000673	0.00132	CcSEcCtD
Vidarabine—Hypersensitivity—Paclitaxel—ovarian cancer	0.000669	0.00132	CcSEcCtD
Vidarabine—Mediastinal disorder—Epirubicin—ovarian cancer	0.000659	0.0013	CcSEcCtD
Vidarabine—Pain—Docetaxel—ovarian cancer	0.000658	0.00129	CcSEcCtD
Vidarabine—Arrhythmia—Epirubicin—ovarian cancer	0.000653	0.00128	CcSEcCtD
Vidarabine—Asthenia—Paclitaxel—ovarian cancer	0.000652	0.00128	CcSEcCtD
Vidarabine—ADA—C-MYB transcription factor network—HRAS—ovarian cancer	0.000645	0.00405	CbGpPWpGaD
Vidarabine—Tinnitus—Doxorubicin—ovarian cancer	0.000631	0.00124	CcSEcCtD
Vidarabine—Cardiac disorder—Doxorubicin—ovarian cancer	0.000628	0.00123	CcSEcCtD
Vidarabine—Flushing—Doxorubicin—ovarian cancer	0.000628	0.00123	CcSEcCtD
Vidarabine—ADORA2A—NGF signalling via TRKA from the plasma membrane—PPP2R1A—ovarian cancer	0.000625	0.00392	CbGpPWpGaD
Vidarabine—Tension—Epirubicin—ovarian cancer	0.000624	0.00123	CcSEcCtD
Vidarabine—Dysgeusia—Epirubicin—ovarian cancer	0.000623	0.00123	CcSEcCtD
Vidarabine—Nervousness—Epirubicin—ovarian cancer	0.000618	0.00122	CcSEcCtD
Vidarabine—Back pain—Epirubicin—ovarian cancer	0.000616	0.00121	CcSEcCtD
Vidarabine—Mediastinal disorder—Doxorubicin—ovarian cancer	0.00061	0.0012	CcSEcCtD
Vidarabine—Arrhythmia—Doxorubicin—ovarian cancer	0.000604	0.00119	CcSEcCtD
Vidarabine—Dizziness—Paclitaxel—ovarian cancer	0.000601	0.00118	CcSEcCtD
Vidarabine—Vision blurred—Epirubicin—ovarian cancer	0.0006	0.00118	CcSEcCtD
Vidarabine—Agitation—Epirubicin—ovarian cancer	0.000585	0.00115	CcSEcCtD
Vidarabine—ADORA2A—Circadian rythm related genes—TYMS—ovarian cancer	0.000581	0.00365	CbGpPWpGaD
Vidarabine—Tension—Doxorubicin—ovarian cancer	0.000578	0.00114	CcSEcCtD
Vidarabine—Vomiting—Paclitaxel—ovarian cancer	0.000578	0.00114	CcSEcCtD
Vidarabine—Dysgeusia—Doxorubicin—ovarian cancer	0.000577	0.00113	CcSEcCtD
Vidarabine—Rash—Paclitaxel—ovarian cancer	0.000573	0.00113	CcSEcCtD
Vidarabine—Dermatitis—Paclitaxel—ovarian cancer	0.000572	0.00113	CcSEcCtD
Vidarabine—Nervousness—Doxorubicin—ovarian cancer	0.000572	0.00112	CcSEcCtD
Vidarabine—Syncope—Epirubicin—ovarian cancer	0.000571	0.00112	CcSEcCtD
Vidarabine—Back pain—Doxorubicin—ovarian cancer	0.00057	0.00112	CcSEcCtD
Vidarabine—Headache—Paclitaxel—ovarian cancer	0.000569	0.00112	CcSEcCtD
Vidarabine—Hypersensitivity—Docetaxel—ovarian cancer	0.000567	0.00112	CcSEcCtD
Vidarabine—Palpitations—Epirubicin—ovarian cancer	0.000562	0.00111	CcSEcCtD
Vidarabine—Loss of consciousness—Epirubicin—ovarian cancer	0.000559	0.0011	CcSEcCtD
Vidarabine—ADA—Metabolism—CYTB—ovarian cancer	0.000557	0.0035	CbGpPWpGaD
Vidarabine—Cough—Epirubicin—ovarian cancer	0.000555	0.00109	CcSEcCtD
Vidarabine—Vision blurred—Doxorubicin—ovarian cancer	0.000555	0.00109	CcSEcCtD
Vidarabine—Asthenia—Docetaxel—ovarian cancer	0.000552	0.00109	CcSEcCtD
Vidarabine—Convulsion—Epirubicin—ovarian cancer	0.000551	0.00108	CcSEcCtD
Vidarabine—Hypertension—Epirubicin—ovarian cancer	0.000549	0.00108	CcSEcCtD
Vidarabine—Chest pain—Epirubicin—ovarian cancer	0.000542	0.00107	CcSEcCtD
Vidarabine—Agitation—Doxorubicin—ovarian cancer	0.000541	0.00106	CcSEcCtD
Vidarabine—Anxiety—Epirubicin—ovarian cancer	0.00054	0.00106	CcSEcCtD
Vidarabine—Nausea—Paclitaxel—ovarian cancer	0.00054	0.00106	CcSEcCtD
Vidarabine—Discomfort—Epirubicin—ovarian cancer	0.000535	0.00105	CcSEcCtD
Vidarabine—Dry mouth—Epirubicin—ovarian cancer	0.00053	0.00104	CcSEcCtD
Vidarabine—Syncope—Doxorubicin—ovarian cancer	0.000528	0.00104	CcSEcCtD
Vidarabine—Palpitations—Doxorubicin—ovarian cancer	0.00052	0.00102	CcSEcCtD
Vidarabine—Anaphylactic shock—Epirubicin—ovarian cancer	0.000519	0.00102	CcSEcCtD
Vidarabine—Loss of consciousness—Doxorubicin—ovarian cancer	0.000517	0.00102	CcSEcCtD
Vidarabine—Cough—Doxorubicin—ovarian cancer	0.000514	0.00101	CcSEcCtD
Vidarabine—Shock—Epirubicin—ovarian cancer	0.000511	0.001	CcSEcCtD
Vidarabine—Convulsion—Doxorubicin—ovarian cancer	0.00051	0.001	CcSEcCtD
Vidarabine—Dizziness—Docetaxel—ovarian cancer	0.000509	0.001	CcSEcCtD
Vidarabine—Hypertension—Doxorubicin—ovarian cancer	0.000508	0.001	CcSEcCtD
Vidarabine—Tachycardia—Epirubicin—ovarian cancer	0.000507	0.000997	CcSEcCtD
Vidarabine—Hyperhidrosis—Epirubicin—ovarian cancer	0.000502	0.000987	CcSEcCtD
Vidarabine—Chest pain—Doxorubicin—ovarian cancer	0.000501	0.000986	CcSEcCtD
Vidarabine—Anxiety—Doxorubicin—ovarian cancer	0.0005	0.000982	CcSEcCtD
Vidarabine—Discomfort—Doxorubicin—ovarian cancer	0.000495	0.000974	CcSEcCtD
Vidarabine—ADA—Circadian rythm related genes—PTEN—ovarian cancer	0.000492	0.00309	CbGpPWpGaD
Vidarabine—Dry mouth—Doxorubicin—ovarian cancer	0.00049	0.000964	CcSEcCtD
Vidarabine—Vomiting—Docetaxel—ovarian cancer	0.00049	0.000963	CcSEcCtD
Vidarabine—ADA—Metabolism—PPP1CC—ovarian cancer	0.000487	0.00306	CbGpPWpGaD
Vidarabine—ADA—Metabolism—BRIP1—ovarian cancer	0.000487	0.00306	CbGpPWpGaD
Vidarabine—Rash—Docetaxel—ovarian cancer	0.000485	0.000955	CcSEcCtD
Vidarabine—Hypotension—Epirubicin—ovarian cancer	0.000485	0.000954	CcSEcCtD
Vidarabine—Dermatitis—Docetaxel—ovarian cancer	0.000485	0.000954	CcSEcCtD
Vidarabine—Headache—Docetaxel—ovarian cancer	0.000482	0.000949	CcSEcCtD
Vidarabine—ADORA2A—Signaling by NGF—PPP2R1A—ovarian cancer	0.000481	0.00302	CbGpPWpGaD
Vidarabine—Anaphylactic shock—Doxorubicin—ovarian cancer	0.000481	0.000945	CcSEcCtD
Vidarabine—ADK—Metabolism—YAP1—ovarian cancer	0.00048	0.00302	CbGpPWpGaD
Vidarabine—Musculoskeletal discomfort—Epirubicin—ovarian cancer	0.000473	0.000931	CcSEcCtD
Vidarabine—Shock—Doxorubicin—ovarian cancer	0.000473	0.00093	CcSEcCtD
Vidarabine—Tachycardia—Doxorubicin—ovarian cancer	0.000469	0.000922	CcSEcCtD
Vidarabine—Paraesthesia—Epirubicin—ovarian cancer	0.000466	0.000917	CcSEcCtD
Vidarabine—Hyperhidrosis—Doxorubicin—ovarian cancer	0.000465	0.000914	CcSEcCtD
Vidarabine—Dyspnoea—Epirubicin—ovarian cancer	0.000463	0.000911	CcSEcCtD
Vidarabine—Somnolence—Epirubicin—ovarian cancer	0.000462	0.000908	CcSEcCtD
Vidarabine—Nausea—Docetaxel—ovarian cancer	0.000457	0.000899	CcSEcCtD
Vidarabine—ADORA2A—Signaling Pathways—HSD17B6—ovarian cancer	0.000454	0.00285	CbGpPWpGaD
Vidarabine—Hypotension—Doxorubicin—ovarian cancer	0.000449	0.000883	CcSEcCtD
Vidarabine—Pain—Epirubicin—ovarian cancer	0.000444	0.000873	CcSEcCtD
Vidarabine—Musculoskeletal discomfort—Doxorubicin—ovarian cancer	0.000438	0.000861	CcSEcCtD
Vidarabine—ADORA2A—NGF signalling via TRKA from the plasma membrane—IL6ST—ovarian cancer	0.000435	0.00273	CbGpPWpGaD
Vidarabine—Adenosine triphosphate—ABCB1—ovarian cancer	0.000434	0.0154	CrCbGaD
Vidarabine—Paraesthesia—Doxorubicin—ovarian cancer	0.000431	0.000849	CcSEcCtD
Vidarabine—Dyspnoea—Doxorubicin—ovarian cancer	0.000428	0.000843	CcSEcCtD
Vidarabine—Somnolence—Doxorubicin—ovarian cancer	0.000427	0.00084	CcSEcCtD
Vidarabine—Urticaria—Epirubicin—ovarian cancer	0.000413	0.000811	CcSEcCtD
Vidarabine—Pain—Doxorubicin—ovarian cancer	0.000411	0.000808	CcSEcCtD
Vidarabine—ADK—Metabolism—FASN—ovarian cancer	0.000392	0.00246	CbGpPWpGaD
Vidarabine—ADORA2A—Signaling Pathways—DLC1—ovarian cancer	0.000386	0.00242	CbGpPWpGaD
Vidarabine—ADK—Metabolism—SLC5A5—ovarian cancer	0.000385	0.00242	CbGpPWpGaD
Vidarabine—Hypersensitivity—Epirubicin—ovarian cancer	0.000383	0.000752	CcSEcCtD
Vidarabine—Urticaria—Doxorubicin—ovarian cancer	0.000382	0.000751	CcSEcCtD
Vidarabine—Asthenia—Epirubicin—ovarian cancer	0.000373	0.000733	CcSEcCtD
Vidarabine—ADK—Metabolism—SLC2A1—ovarian cancer	0.000372	0.00234	CbGpPWpGaD
Vidarabine—ADORA2A—NGF signalling via TRKA from the plasma membrane—PIK3CD—ovarian cancer	0.000368	0.00231	CbGpPWpGaD
Vidarabine—ADK—Metabolism—CYP1B1—ovarian cancer	0.000357	0.00224	CbGpPWpGaD
Vidarabine—Hypersensitivity—Doxorubicin—ovarian cancer	0.000354	0.000696	CcSEcCtD
Vidarabine—Asthenia—Doxorubicin—ovarian cancer	0.000345	0.000678	CcSEcCtD
Vidarabine—Dizziness—Epirubicin—ovarian cancer	0.000343	0.000675	CcSEcCtD
Vidarabine—ADA—Circadian rythm related genes—TP53—ovarian cancer	0.000336	0.00211	CbGpPWpGaD
Vidarabine—ADORA2A—Signaling by NGF—IL6ST—ovarian cancer	0.000335	0.0021	CbGpPWpGaD
Vidarabine—Vomiting—Epirubicin—ovarian cancer	0.00033	0.000649	CcSEcCtD
Vidarabine—Rash—Epirubicin—ovarian cancer	0.000327	0.000644	CcSEcCtD
Vidarabine—Dermatitis—Epirubicin—ovarian cancer	0.000327	0.000643	CcSEcCtD
Vidarabine—ADA—Metabolism—YAP1—ovarian cancer	0.000327	0.00205	CbGpPWpGaD
Vidarabine—Headache—Epirubicin—ovarian cancer	0.000325	0.00064	CcSEcCtD
Vidarabine—ADORA2A—NGF signalling via TRKA from the plasma membrane—ERBB2—ovarian cancer	0.000325	0.00204	CbGpPWpGaD
Vidarabine—ADORA2A—NGF signalling via TRKA from the plasma membrane—PIK3CB—ovarian cancer	0.000321	0.00201	CbGpPWpGaD
Vidarabine—ADORA2A—NGF signalling via TRKA from the plasma membrane—MTOR—ovarian cancer	0.000321	0.00201	CbGpPWpGaD
Vidarabine—Dizziness—Doxorubicin—ovarian cancer	0.000318	0.000625	CcSEcCtD
Vidarabine—ADK—Metabolism—PPP2R1A—ovarian cancer	0.000316	0.00199	CbGpPWpGaD
Vidarabine—ADORA2A—Signaling Pathways—BCL9—ovarian cancer	0.000315	0.00197	CbGpPWpGaD
Vidarabine—Nausea—Epirubicin—ovarian cancer	0.000308	0.000607	CcSEcCtD
Vidarabine—ADA—Circadian rythm related genes—IL6—ovarian cancer	0.000307	0.00193	CbGpPWpGaD
Vidarabine—Vomiting—Doxorubicin—ovarian cancer	0.000306	0.000601	CcSEcCtD
Vidarabine—Rash—Doxorubicin—ovarian cancer	0.000303	0.000596	CcSEcCtD
Vidarabine—Dermatitis—Doxorubicin—ovarian cancer	0.000303	0.000595	CcSEcCtD
Vidarabine—Headache—Doxorubicin—ovarian cancer	0.000301	0.000592	CcSEcCtD
Vidarabine—ADORA2A—NGF signalling via TRKA from the plasma membrane—CDKN1B—ovarian cancer	0.000301	0.00189	CbGpPWpGaD
Vidarabine—DPP4—Metabolism of proteins—MMP2—ovarian cancer	0.000297	0.00186	CbGpPWpGaD
Vidarabine—ADK—Metabolism—ABCB1—ovarian cancer	0.000294	0.00184	CbGpPWpGaD
Vidarabine—ADK—Metabolism—TYMS—ovarian cancer	0.000288	0.00181	CbGpPWpGaD
Vidarabine—Nausea—Doxorubicin—ovarian cancer	0.000285	0.000561	CcSEcCtD
Vidarabine—ADORA2A—Signaling by NGF—PIK3CD—ovarian cancer	0.000283	0.00178	CbGpPWpGaD
Vidarabine—ADORA2A—Circadian rythm related genes—PTEN—ovarian cancer	0.000283	0.00177	CbGpPWpGaD
Vidarabine—ADORA2A—NGF signalling via TRKA from the plasma membrane—PTEN—ovarian cancer	0.000277	0.00174	CbGpPWpGaD
Vidarabine—ADA—Metabolism—FASN—ovarian cancer	0.000266	0.00167	CbGpPWpGaD
Vidarabine—ADA—Metabolism—SLC5A5—ovarian cancer	0.000262	0.00164	CbGpPWpGaD
Vidarabine—ADA—Metabolism—SLC2A1—ovarian cancer	0.000253	0.00159	CbGpPWpGaD
Vidarabine—ADORA2A—Signaling by NGF—ERBB2—ovarian cancer	0.00025	0.00157	CbGpPWpGaD
Vidarabine—ADORA2A—Signaling Pathways—DOK1—ovarian cancer	0.000249	0.00156	CbGpPWpGaD
Vidarabine—ADORA2A—NGF signalling via TRKA from the plasma membrane—STAT3—ovarian cancer	0.000248	0.00156	CbGpPWpGaD
Vidarabine—ADORA2A—NGF signalling via TRKA from the plasma membrane—NRAS—ovarian cancer	0.000247	0.00155	CbGpPWpGaD
Vidarabine—DPP4—Metabolism of proteins—CXCL8—ovarian cancer	0.000247	0.00155	CbGpPWpGaD
Vidarabine—ADORA2A—Signaling by NGF—MTOR—ovarian cancer	0.000247	0.00155	CbGpPWpGaD
Vidarabine—ADORA2A—Signaling by NGF—PIK3CB—ovarian cancer	0.000247	0.00155	CbGpPWpGaD
Vidarabine—ADA—Metabolism—CYP1B1—ovarian cancer	0.000242	0.00152	CbGpPWpGaD
Vidarabine—ADORA2A—NGF signalling via TRKA from the plasma membrane—MAPK3—ovarian cancer	0.000237	0.00149	CbGpPWpGaD
Vidarabine—ADORA2A—Signaling Pathways—PPP1CC—ovarian cancer	0.000234	0.00147	CbGpPWpGaD
Vidarabine—ADK—Metabolism—CAV1—ovarian cancer	0.000232	0.00146	CbGpPWpGaD
Vidarabine—ADORA2A—Signaling by NGF—CDKN1B—ovarian cancer	0.000231	0.00145	CbGpPWpGaD
Vidarabine—DPP4—Metabolism of proteins—CTNNB1—ovarian cancer	0.000227	0.00143	CbGpPWpGaD
Vidarabine—ADORA2A—Signaling by NGF—CASP3—ovarian cancer	0.000227	0.00142	CbGpPWpGaD
Vidarabine—ADORA2A—NGF signalling via TRKA from the plasma membrane—MAPK1—ovarian cancer	0.000225	0.00141	CbGpPWpGaD
Vidarabine—ADORA2A—NGF signalling via TRKA from the plasma membrane—EGFR—ovarian cancer	0.000225	0.00141	CbGpPWpGaD
Vidarabine—ADORA2A—Class A/1 (Rhodopsin-like receptors)—CXCL8—ovarian cancer	0.00022	0.00138	CbGpPWpGaD
Vidarabine—ADA—Metabolism—PPP2R1A—ovarian cancer	0.000215	0.00135	CbGpPWpGaD
Vidarabine—ADORA2A—Signaling by NGF—PTEN—ovarian cancer	0.000213	0.00134	CbGpPWpGaD
Vidarabine—ADORA2A—NGF signalling via TRKA from the plasma membrane—KRAS—ovarian cancer	0.000213	0.00134	CbGpPWpGaD
Vidarabine—ADK—Metabolism—PIK3CG—ovarian cancer	0.000212	0.00133	CbGpPWpGaD
Vidarabine—ADA—Metabolism—ABCB1—ovarian cancer	0.0002	0.00125	CbGpPWpGaD
Vidarabine—ADA—Metabolism—TYMS—ovarian cancer	0.000196	0.00123	CbGpPWpGaD
Vidarabine—ADORA2A—NGF signalling via TRKA from the plasma membrane—PIK3CA—ovarian cancer	0.000195	0.00123	CbGpPWpGaD
Vidarabine—ADORA2A—Circadian rythm related genes—TP53—ovarian cancer	0.000193	0.00121	CbGpPWpGaD
Vidarabine—ADORA2A—Signaling by NGF—STAT3—ovarian cancer	0.000191	0.0012	CbGpPWpGaD
Vidarabine—ADORA2A—Signaling by NGF—NRAS—ovarian cancer	0.00019	0.00119	CbGpPWpGaD
Vidarabine—ADK—Metabolism—PIK3CD—ovarian cancer	0.000186	0.00117	CbGpPWpGaD
Vidarabine—ADORA2A—Signaling by NGF—MAPK3—ovarian cancer	0.000182	0.00114	CbGpPWpGaD
Vidarabine—ADORA2A—NGF signalling via TRKA from the plasma membrane—HRAS—ovarian cancer	0.000181	0.00113	CbGpPWpGaD
Vidarabine—ADORA2A—Signaling Pathways—HDAC6—ovarian cancer	0.000177	0.00111	CbGpPWpGaD
Vidarabine—ADORA2A—Circadian rythm related genes—IL6—ovarian cancer	0.000176	0.00111	CbGpPWpGaD
Vidarabine—ADORA2A—Signaling by GPCR—PPP2R1A—ovarian cancer	0.000175	0.0011	CbGpPWpGaD
Vidarabine—ADORA2A—Signaling by NGF—MAPK1—ovarian cancer	0.000173	0.00109	CbGpPWpGaD
Vidarabine—ADORA2A—Signaling by NGF—EGFR—ovarian cancer	0.000173	0.00109	CbGpPWpGaD
Vidarabine—ADORA2A—NGF signalling via TRKA from the plasma membrane—IL6—ovarian cancer	0.000173	0.00109	CbGpPWpGaD
Vidarabine—ADORA2A—GPCR ligand binding—CXCL8—ovarian cancer	0.000168	0.00105	CbGpPWpGaD
Vidarabine—ADORA2A—Signaling by NGF—KRAS—ovarian cancer	0.000164	0.00103	CbGpPWpGaD
Vidarabine—ADK—Metabolism—PIK3CB—ovarian cancer	0.000162	0.00102	CbGpPWpGaD
Vidarabine—ADORA2A—NGF signalling via TRKA from the plasma membrane—AKT1—ovarian cancer	0.00016	0.001	CbGpPWpGaD
Vidarabine—ADA—Metabolism—CAV1—ovarian cancer	0.000158	0.000992	CbGpPWpGaD
Vidarabine—ADORA2A—Signaling Pathways—YAP1—ovarian cancer	0.000157	0.000984	CbGpPWpGaD
Vidarabine—ADORA2A—Signaling Pathways—XIAP—ovarian cancer	0.000154	0.000964	CbGpPWpGaD
Vidarabine—ADORA2A—Signaling by NGF—PIK3CA—ovarian cancer	0.00015	0.000944	CbGpPWpGaD
Vidarabine—ADORA2A—Signaling Pathways—SMARCA4—ovarian cancer	0.00015	0.00094	CbGpPWpGaD
Vidarabine—ADORA2A—Signaling Pathways—EREG—ovarian cancer	0.000146	0.000917	CbGpPWpGaD
Vidarabine—ADA—Metabolism—PIK3CG—ovarian cancer	0.000144	0.000903	CbGpPWpGaD
Vidarabine—ADK—Metabolism—PTEN—ovarian cancer	0.00014	0.00088	CbGpPWpGaD
Vidarabine—ADORA2A—Signaling by NGF—HRAS—ovarian cancer	0.000139	0.000873	CbGpPWpGaD
Vidarabine—ADORA2A—Signaling Pathways—PGR—ovarian cancer	0.000137	0.00086	CbGpPWpGaD
Vidarabine—ADORA2A—Signaling by NGF—IL6—ovarian cancer	0.000133	0.000835	CbGpPWpGaD
Vidarabine—ADORA2A—GPCR downstream signaling—PIK3CG—ovarian cancer	0.000129	0.000809	CbGpPWpGaD
Vidarabine—ADORA2A—Signaling Pathways—PARP1—ovarian cancer	0.000127	0.000799	CbGpPWpGaD
Vidarabine—ADA—Metabolism—PIK3CD—ovarian cancer	0.000127	0.000794	CbGpPWpGaD
Vidarabine—ADORA2A—Signaling by NGF—AKT1—ovarian cancer	0.000123	0.000771	CbGpPWpGaD
Vidarabine—ADORA2A—Signaling by GPCR—IL6ST—ovarian cancer	0.000122	0.000764	CbGpPWpGaD
Vidarabine—ADORA2A—Signaling by GPCR—PIK3CG—ovarian cancer	0.000117	0.000734	CbGpPWpGaD
Vidarabine—ADORA2A—GPCR downstream signaling—PIK3CD—ovarian cancer	0.000113	0.000711	CbGpPWpGaD
Vidarabine—ADA—Metabolism—PIK3CB—ovarian cancer	0.00011	0.000692	CbGpPWpGaD
Vidarabine—ADORA2A—Signaling Pathways—PPP2R1A—ovarian cancer	0.000103	0.000648	CbGpPWpGaD
Vidarabine—ADORA2A—Signaling by GPCR—PIK3CD—ovarian cancer	0.000103	0.000646	CbGpPWpGaD
Vidarabine—ADK—Metabolism—PIK3CA—ovarian cancer	9.89e-05	0.000621	CbGpPWpGaD
Vidarabine—ADORA2A—GPCR downstream signaling—PIK3CB—ovarian cancer	9.87e-05	0.00062	CbGpPWpGaD
Vidarabine—ADA—Metabolism—PTEN—ovarian cancer	9.53e-05	0.000598	CbGpPWpGaD
Vidarabine—ADORA2A—GPCR downstream signaling—CXCL8—ovarian cancer	9.49e-05	0.000595	CbGpPWpGaD
Vidarabine—ADORA2A—GPCR downstream signaling—IL2—ovarian cancer	9.07e-05	0.000569	CbGpPWpGaD
Vidarabine—ADORA2A—Signaling by GPCR—PIK3CB—ovarian cancer	8.96e-05	0.000563	CbGpPWpGaD
Vidarabine—ADORA2A—Signaling by GPCR—CXCL8—ovarian cancer	8.61e-05	0.000541	CbGpPWpGaD
Vidarabine—ADORA2A—Signaling by GPCR—IL2—ovarian cancer	8.23e-05	0.000517	CbGpPWpGaD
Vidarabine—ADORA2A—Signaling Pathways—TERT—ovarian cancer	8.2e-05	0.000515	CbGpPWpGaD
Vidarabine—ADK—Metabolism—AKT1—ovarian cancer	8.08e-05	0.000507	CbGpPWpGaD
Vidarabine—ADORA2A—Signaling Pathways—CAV1—ovarian cancer	7.59e-05	0.000476	CbGpPWpGaD
Vidarabine—ADORA2A—Signaling Pathways—ESR1—ovarian cancer	7.31e-05	0.000459	CbGpPWpGaD
Vidarabine—ADORA2A—Signaling Pathways—IL6ST—ovarian cancer	7.19e-05	0.000452	CbGpPWpGaD
Vidarabine—ADORA2A—Signaling Pathways—APC—ovarian cancer	6.91e-05	0.000434	CbGpPWpGaD
Vidarabine—ADORA2A—Signaling Pathways—PIK3CG—ovarian cancer	6.91e-05	0.000434	CbGpPWpGaD
Vidarabine—ADORA2A—Signaling by GPCR—NRAS—ovarian cancer	6.91e-05	0.000434	CbGpPWpGaD
Vidarabine—ADA—Metabolism—PIK3CA—ovarian cancer	6.72e-05	0.000422	CbGpPWpGaD
Vidarabine—ADORA2A—Signaling by GPCR—MAPK3—ovarian cancer	6.62e-05	0.000415	CbGpPWpGaD
Vidarabine—ADORA2A—Signaling by GPCR—MAPK1—ovarian cancer	6.3e-05	0.000395	CbGpPWpGaD
Vidarabine—ADORA2A—Signaling by GPCR—EGFR—ovarian cancer	6.3e-05	0.000395	CbGpPWpGaD
Vidarabine—ADORA2A—Signaling Pathways—PIK3CD—ovarian cancer	6.08e-05	0.000381	CbGpPWpGaD
Vidarabine—ADORA2A—GPCR downstream signaling—PIK3CA—ovarian cancer	6.02e-05	0.000378	CbGpPWpGaD
Vidarabine—ADORA2A—Signaling by GPCR—KRAS—ovarian cancer	5.95e-05	0.000373	CbGpPWpGaD
Vidarabine—ADA—Metabolism—AKT1—ovarian cancer	5.49e-05	0.000345	CbGpPWpGaD
Vidarabine—ADORA2A—Signaling by GPCR—PIK3CA—ovarian cancer	5.46e-05	0.000343	CbGpPWpGaD
Vidarabine—ADORA2A—Signaling Pathways—ERBB2—ovarian cancer	5.37e-05	0.000337	CbGpPWpGaD
Vidarabine—ADORA2A—Signaling Pathways—PIK3CB—ovarian cancer	5.3e-05	0.000332	CbGpPWpGaD
Vidarabine—ADORA2A—Signaling Pathways—MTOR—ovarian cancer	5.3e-05	0.000332	CbGpPWpGaD
Vidarabine—ADORA2A—Signaling Pathways—CXCL8—ovarian cancer	5.09e-05	0.000319	CbGpPWpGaD
Vidarabine—ADORA2A—Signaling by GPCR—HRAS—ovarian cancer	5.06e-05	0.000317	CbGpPWpGaD
Vidarabine—ADORA2A—Signaling Pathways—CDKN1B—ovarian cancer	4.97e-05	0.000312	CbGpPWpGaD
Vidarabine—ADORA2A—GPCR downstream signaling—AKT1—ovarian cancer	4.92e-05	0.000309	CbGpPWpGaD
Vidarabine—ADORA2A—Signaling Pathways—CASP3—ovarian cancer	4.87e-05	0.000306	CbGpPWpGaD
Vidarabine—ADORA2A—Signaling Pathways—IL2—ovarian cancer	4.86e-05	0.000305	CbGpPWpGaD
Vidarabine—ADORA2A—Signaling by GPCR—IL6—ovarian cancer	4.84e-05	0.000304	CbGpPWpGaD
Vidarabine—ADORA2A—Signaling Pathways—CCND1—ovarian cancer	4.74e-05	0.000298	CbGpPWpGaD
Vidarabine—ADORA2A—Signaling Pathways—CTNNB1—ovarian cancer	4.7e-05	0.000295	CbGpPWpGaD
Vidarabine—ADORA2A—Signaling Pathways—MMP9—ovarian cancer	4.6e-05	0.000289	CbGpPWpGaD
Vidarabine—ADORA2A—Signaling Pathways—PTEN—ovarian cancer	4.58e-05	0.000287	CbGpPWpGaD
Vidarabine—ADORA2A—Signaling by GPCR—AKT1—ovarian cancer	4.46e-05	0.00028	CbGpPWpGaD
Vidarabine—ADORA2A—Signaling Pathways—VEGFA—ovarian cancer	4.13e-05	0.000259	CbGpPWpGaD
Vidarabine—ADORA2A—Signaling Pathways—STAT3—ovarian cancer	4.09e-05	0.000257	CbGpPWpGaD
Vidarabine—ADORA2A—Signaling Pathways—NRAS—ovarian cancer	4.08e-05	0.000256	CbGpPWpGaD
Vidarabine—ADORA2A—Signaling Pathways—MAPK3—ovarian cancer	3.91e-05	0.000245	CbGpPWpGaD
Vidarabine—ADORA2A—Signaling Pathways—MYC—ovarian cancer	3.8e-05	0.000239	CbGpPWpGaD
Vidarabine—ADORA2A—Signaling Pathways—MAPK1—ovarian cancer	3.72e-05	0.000234	CbGpPWpGaD
Vidarabine—ADORA2A—Signaling Pathways—EGFR—ovarian cancer	3.72e-05	0.000233	CbGpPWpGaD
Vidarabine—ADORA2A—Signaling Pathways—KRAS—ovarian cancer	3.51e-05	0.000221	CbGpPWpGaD
Vidarabine—ADORA2A—Signaling Pathways—PIK3CA—ovarian cancer	3.23e-05	0.000203	CbGpPWpGaD
Vidarabine—ADORA2A—Signaling Pathways—TP53—ovarian cancer	3.12e-05	0.000196	CbGpPWpGaD
Vidarabine—ADORA2A—Signaling Pathways—HRAS—ovarian cancer	2.99e-05	0.000187	CbGpPWpGaD
Vidarabine—ADORA2A—Signaling Pathways—IL6—ovarian cancer	2.86e-05	0.000179	CbGpPWpGaD
Vidarabine—ADORA2A—Signaling Pathways—AKT1—ovarian cancer	2.64e-05	0.000166	CbGpPWpGaD
